Immunome IMNM
NASDAQ IMNM
$20.90 +0.01 (+0.05%)
At close: Oct 2, 2026 · 4:00 PM EDT

Immunome (IMNM) Gains from Sales and Divestitures (2025 - 2026)

Updated

Immunome (IMNM) reported Gains from Sales and Divestitures of $1,000 for Q2 2026, compared with -$891,000 a year earlier.

Analysis

Immunome (IMNM) Gains from Sales and Divestitures (2025 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Immunome's Gains from Sales and Divestitures came in at -$83,000; for FY2025, it was -$896,000.

  • Five-year quarterly Gains from Sales and Divestitures spans a low of -$891,000 in Q2 2025 and a high of $50,000 in Q3 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -$79,000 (Q1 2026), -$55,000 (Q4 2025) and $50,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Immunome 2.37 Bn 341.22 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1,000.00
Mar 31, 2026 -79,000.00
Dec 31, 2025 -55,000.00
Sep 30, 2025 50,000.00
Jun 30, 2025 -891,000.00
API Access

Immunome Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=IMNM&period=max&api_key=YOUR_API_KEY